CLU and prostate carcinoma: Overexpression of CLU in OS indicates drug resistance to conventional therapies [23, 27] and over-expression of CLU in prostate cancer cells accelerates progression after hormone- or chemo-therapy [19, 24], identifying CLU as an anti-apoptotic gene up-regulated by treatment stress that confers therapeutic resistance.